Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-03-30

FDA Approved: TRADJENTA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Tradjenta (linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc., resulting in an update to the drug's la…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tradjenta (Linagliptin)

Snippet

SUPPL AP for TRADJENTA (LINAGLIPTIN)